Total Valuation
Biogen has a market cap or net worth of €32.34B. The enterprise value is €39.88B.
Market Cap€32.34B
Enterprise Value€39.88B
Share Statistics
Biogen has 147,754,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding147,754,000
Owned by Insiders0.18%
Owned by Institutions2.07%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 6.62%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)6.62%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.31M
Profits Per Employee172.39K
Employee Count7,500
Asset Turnover0.33
Inventory Turnover1.34
Valuation Ratios
The current PE Ratio of Biogen is 1.6. Biogen’s PEG ratio is -0.95.
PE Ratio1.6
PS Ratio2.63
PB Ratio1.41
Price to FCF12.59
Price to Operating Cash Flow16.04
PEG Ratio-0.95
Income Statement
In the last 12 months, Biogen had revenue of 9.81B and earned 1.29B in profits. Earnings per share was 8.85.
Revenue9.81B
Gross Profit6.91B
Operating Income1.88B
Pretax Income1.40B
Net Income1.29B
EBITDA2.95B
Earnings Per Share (EPS)8.85
Cash Flow
In the last 12 months, operating cash flow was 2.25B and capital expenditures 176.40M, giving a free cash flow of 2.42B billion.
Operating Cash Flow2.25B
Free Cash Flow2.42B
Free Cash Flow per Share16.40
Dividends & Yields
Biogen pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change73.48%
50-Day Moving Average197.90
200-Day Moving Average173.74
Relative Strength Index (RSI)65.54
Average Volume (3m)113.00
Important Dates
Biogen upcoming earnings date is Feb 17, 2027, Before Open (Confirmed).
Last Earnings DateOct 28, 2026
Next Earnings DateFeb 17, 2027
Ex-Dividend Date―
Financial Position
Biogen as a current ratio of 2.68, with Debt / Equity ratio of 41.23%
Current Ratio2.68
Quick Ratio2.03
Debt to Market Cap0.26
Net Debt to EBITDA1.34
Interest Coverage Ratio7.63
Taxes
In the past 12 months, Biogen has paid 108.11M in taxes.
Income Tax108.11M
Effective Tax Rate0.08
Enterprise Valuation
Biogen EV to EBITDA ratio is 10.10, with an EV/FCF ratio of 14.51.
EV to Sales3.03
EV to EBITDA10.10
EV to Free Cash Flow14.51
EV to Operating Cash Flow13.50
Balance Sheet
Biogen has €1.30B in cash and marketable securities with €7.80B in debt, giving a net cash position of -€6.50B billion.
Cash & Marketable Securities€1.30B
Total Debt€7.80B
Net Cash-€6.50B
Net Cash Per Share-€43.97
Tangible Book Value Per Share€17.64
Margins
Gross margin is 70.05%, with operating margin of 19.14%, and net profit margin of 13.18%.
Gross Margin70.05%
Operating Margin19.14%
Pretax Margin14.29%
Net Profit Margin13.18%
EBITDA Margin30.02%
EBIT Margin22.07%
Analyst Forecast
The average price target for Biogen is €224.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€224.65
Price Target Upside19.54% Upside
Analyst ConsensusModerate Buy
Analyst Count22
Revenue Growth Forecast-2.84%
EPS Growth Forecast-79.49%